세계의 말초신경 손상(PNI) 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 수술별, 용도별, 지역별, 부문 예측(2025-2030년)

Peripheral Nerve Injury Market Size, Share & Trends Analysis Report By Product (Nerve Conduit, Nerve Protector), By Surgery (Direct Nerve Repair, Nerve Grafting, Stem Cell Therapy), By Application, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,404,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,816,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,641,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

말초신경손상 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면, 세계 말초신경 손상 시장 규모는 2030년까지 25억 8,000만 달러에 달하고, 2025년부터 2030년까지 7.80%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.

코로나19는 시장에 악영향을 미쳐 수요와 생산에 직접적인 영향을 미치고, 공급망을 혼란에 빠뜨리고, 기업의 경제적 부담을 가중시키고 있습니다. 코로나19가 유행하는 동안 코로나19의 확산을 막기 위해 많은 수술이 정기적으로 연기 및/또는 취소되었습니다. 미국, 러시아, 인도, 브라질, 프랑스, 영국, 이탈리아, 스페인 등 가장 큰 피해를 입은 국가에서는 신경외과 수술이 55% 감소했습니다.

또한, 전국적인 봉쇄로 인해 제조 활동, 공급망, 배송 일정, 생체 재료 판매에 혼란이 발생했습니다. 향후 업계 기업들이 새롭고 우수한 기술을 도입함에 따라 예측 기간 동안 업계는 성장할 것으로 예측됩니다. 예를 들어, 2022년 5월, PNI에 대한 획기적인 수술 솔루션을 마케팅하고 개발하는 세계 선도기업인 Axogen, Inc.의 탑라인 결과가 공개되었습니다. 정적 2점 식별으로 정의되는 감각 기능 회복에 대한 주요 목표는 3상 임상 3상의 중요한 연구에서 달성되었으며, 안전성 프로파일은 이전에 보고된 데이터와 동등하게 나타났습니다. 이 정보는 2023년 하반기 생물학적 제제 승인 신청(BLA)을 제출하는 데 도움이 될 것으로 보입니다.

말초신경 손상 시장 보고서 하이라이트

• 신경도관이 시장을 주도하고 있으며, 2024년 매출 점유율은 64.30%를 웃돌았습니다..
• 직접 신경복원 부문이 시장을 주도하고 있으며, 2024년 세계 매출 점유율은 53.26% 이상에 달했습니다.
• 상지 부문은 2024년에 가장 큰 시장 점유율을 차지했고, 2025년부터 2030년까지 가장 빠른 CAGR로 성장할 것으로 예측됩니다.
• 북미는 2024년 시장에서 30.43% 이상의 가장 큰 매출 점유율을 차지했습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 말초신경 손상(PNI) 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 말초신경 손상(PNI) 시장 분석 툴
  • 업계 분석 - Porter의 Five Forces 분석
  • PESTEL 분석

제4장 말초신경 손상(PNI) 시장 : 제품 추정·동향 분석

• 정의와 범위
• 제품 시장 점유율, 2024년과 2030년
• 부문 대시보드
• 말초신경 손상(PNI) 시장 : 제품 전망 별
• 시장 규모와 예측 및 동향 분석(2018-2030년)
  • 신경도관
  • 신경 보호제
  • 신경 커넥터
  • 신경 붕대

제5장 말초신경 손상(PNI) 시장 : 수술 추정·동향 분석

• 정의와 범위
• 수술 시장 점유율, 2024년과 2030년
• 부문 대시보드
• 말초신경 손상(PNI) 시장 : 수술별 전망
• 시장 규모와 예측 및 동향 분석(2018-2030년)
  • 직접 신경 수복
  • 신경 이식
  • 줄기세포 요법

제6장 말초신경 손상(PNI) 시장 : 용도 추정·동향 분석

• 정의와 범위
• 용도 시장 점유율, 2024년 및 2030년
• 부문 대시보드
• 말초신경 손상(PNI) 시장 : 용도별 전망
• 시장 규모와 예측 및 동향 분석(2018-2030년)
  • 상지
  • 하지

제7장 말초신경 손상(PNI) 시장 : 지역 추정·동향 분석

• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역 시장 대시보드
• 세계 지역 시장 스냅숏
• 지역별 시장 점유율과 주요 기업-(2024년)
• 시장 용도, 예측, 동향 분석, 2018-2030년까지 :
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 인도
  • 중국
  • 한국
  • 호주
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제8장 경쟁 구도

• 주요 시장 진출기업의 최근 동향과 영향 분석
• 기업/경쟁 분류
  • 혁신기업
• 벤더 구도
  • 주요 유통업체 및 채널 파트너 리스트
  • 주요 고객
  • 주요 기업의 시장 점유율 분석(2024년)
  • AxoGen, Inc.
  • Stryker
  • Baxter International, Inc.
  • Polyganics BV
  • Integra LifeSciences
  • Renerva, LLC.
  • Newrotex
  • Toyobo Co., Ltd.
  • Orthocell Ltd

LSH

영문 목차

영문목차

Peripheral Nerve Injury Market Growth & Trends:

The global peripheral nerve injury market size is estimated to reach USD 2.58 billion by 2030, registering to grow at a CAGR of 7.80% from 2025 to 2030 according to a new report by Grand View Research, Inc. COVID-19 has had a negative impact on the market, affecting the demand and production directly, disrupting the supply chain, and increasing the financial burden on businesses. During the pandemic, a number of surgeries were regularly postponed and/or canceled to prevent the spread of COVID-19. Neurosurgical procedures decreased by 55% in the worst-hit countries, including the U.S., Russia, India, Brazil, France, the U.K., Italy, and Spain.

Furthermore, manufacturing activities, supply chain, delivery schedules, and sale of biomaterials were disrupted due to nationwide lockdowns. Moving forward, as industry players are introducing new and better technologies, the industry is expected to grow over the forecast period. For instance, in May 2022, the topline results of Clinical Study Axogen's RECON comparing conduits to Avance Nerve Graft in digital nerve injuries were disclosed by Axogen, Inc., a global pioneer in marketing and developing revolutionary surgical solutions for PNIs. The primary target for the recovery of sensory function, as defined by static two-point discrimination, was fulfilled in Phase 3 pivotal research, and the safety profile was comparable with previously reported data. This information will help the company submit a Biologics License Application (BLA) in the second half of 2023.

Peripheral Nerve Injury Market Report Highlights:

• The nerve conduit led the market and accounted for a more than 64.30% revenue share in 2024.
• The direct nerve repair segment led the market and accounted for more than 53.26% share of the global revenue in 2024.
• The upper extremities segment accounted for the largest market share in 2024 and is anticipated to grow further at the fastest CAGR from 2025 to 2030.
• North America held the largest revenue share of more than 30.43% in the market in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
    • 1.3.5.1. Data for primary interviews in North America
    • 1.3.5.2. Data for primary interviews in Europe
    • 1.3.5.3. Data for primary interviews in Asia Pacific
    • 1.3.5.4. Data for primary interviews in Latin America
    • 1.3.5.5. Data for Primary interviews in MEA
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Surgery outlook
  • 2.2.3. Application outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Peripheral Nerve Injury Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing government fundings and reimbursements
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. Rising medical tourism
    • 3.2.1.4. Increasing demand for 3D bioprinting approach
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Lack of awareness in the patients for treatment of peripheral nerve injury
    • 3.2.2.2. High cost of the treatment and unavailability of trained medical personnel
• 3.3. Peripheral Nerve Injury Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Peripheral Nerve Injury Market: Product Estimates & Trend Analysis

• 4.1. Definitions and Scope
• 4.2. Product Market Share, 2024 & 2030
• 4.3. Segment Dashboard
• 4.4. Peripheral Nerve Injury Market by Product Outlook
• 4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5.1. Nerve Conduit
    • 4.5.1.1. Nerve conduit market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.2. Nerve Protector
    • 4.5.2.1. Nerve protector market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.3. Nerve Connector
    • 4.5.3.1. Nerve connector market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5.4. Nerve Wraps
    • 4.5.4.1. Nerve wraps market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Peripheral Nerve Injury Market: Surgery Estimates & Trend Analysis

• 5.1. Definitions and Scope
• 5.2. Surgery Market Share, 2024 & 2030
• 5.3. Segment Dashboard
• 5.4. Peripheral Nerve Injury Market by Surgery Outlook
• 5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5.1. Direct Nerve Repair
    • 5.5.1.1. Direct nerve repair market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5.2. Nerve Grafting
    • 5.5.2.1. Nerve grafting market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5.3. Stem Cell Therapy
    • 5.5.3.1. Stem cell therapy market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Peripheral Nerve Injury Market: Application Estimates & Trend Analysis

• 6.1. Definitions and Scope
• 6.2. Application Market Share, 2024 & 2030
• 6.3. Segment Dashboard
• 6.4. Peripheral Nerve Injury Market by Application Outlook
• 6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5.1. Upper Extremities
    • 6.5.1.1. Upper extremities market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.2. Lower Extremities
    • 6.5.2.1. Lower extremities market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Peripheral Nerve Injury Market: Regional Estimates & Trend Analysis

• 7.1. Regional market share analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Regional Market Share and Leading Players, 2024
• 7.5. Market Application, & Forecasts and Trend Analysis, 2018 to 2030:
• 7.6. North America
  • 7.6.1. Market estimates and forecast, 2018 - 2030 (Revenue, USD Million)
  • 7.6.2. U.S.
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. U.S. market estimates and forecasts, 2018 - 2030
  • 7.6.3. Canada
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Canada market estimates and forecasts, 2018 - 2030
  • 7.6.4. Mexico
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. Mexico market estimates and forecasts, 2018 - 2030
• 7.7. Europe
  • 7.7.1. UK
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Competitive scenario
    • 7.7.1.3. Regulatory framework
    • 7.7.1.4. Reimbursement scenario
    • 7.7.1.5. UK market estimates and forecasts, 2018 - 2030
  • 7.7.2. Germany
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. Germany market estimates and forecasts, 2018 - 2030
  • 7.7.3. France
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. France market estimates and forecasts, 2018 - 2030
  • 7.7.4. Italy
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. Italy market estimates and forecasts, 2018 - 2030
  • 7.7.5. Spain
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. Spain market estimates and forecasts, 2018 - 2030
  • 7.7.6. Denmark
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Competitive scenario
    • 7.7.6.3. Regulatory framework
    • 7.7.6.4. Reimbursement scenario
    • 7.7.6.5. Denmark market estimates and forecasts, 2018 - 2030
  • 7.7.7. Sweden
    • 7.7.7.1. Key country dynamics
    • 7.7.7.2. Competitive scenario
    • 7.7.7.3. Regulatory framework
    • 7.7.7.4. Reimbursement scenario
    • 7.7.7.5. Sweden market estimates and forecasts, 2018 - 2030
  • 7.7.8. Norway
    • 7.7.8.1. Key country dynamics
    • 7.7.8.2. Competitive scenario
    • 7.7.8.3. Regulatory framework
    • 7.7.8.4. Reimbursement scenario
    • 7.7.8.5. Norway market estimates and forecasts, 2018 - 2030
• 7.8. Asia Pacific
  • 7.8.1. Japan
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Competitive scenario
    • 7.8.1.3. Regulatory framework
    • 7.8.1.4. Reimbursement scenario
    • 7.8.1.5. Japan market estimates and forecasts, 2018 - 2030
  • 7.8.2. India
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. India market estimates and forecasts, 2018 - 2030
  • 7.8.3. China
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Regulatory framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. China market estimates and forecasts, 2018 - 2030
  • 7.8.4. South Korea
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Regulatory framework
    • 7.8.4.4. Reimbursement scenario
    • 7.8.4.5. South Korea market estimates and forecasts, 2018 - 2030
  • 7.8.5. Australia
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Competitive scenario
    • 7.8.5.3. Regulatory framework
    • 7.8.5.4. Reimbursement scenario
    • 7.8.5.5. Australia market estimates and forecasts, 2018 - 2030
  • 7.8.6. Thailand
    • 7.8.6.1. Key country dynamics
    • 7.8.6.2. Competitive scenario
    • 7.8.6.3. Regulatory framework
    • 7.8.6.4. Reimbursement scenario
    • 7.8.6.5. Thailand market estimates and forecasts, 2018 - 2030
• 7.9. Latin America
  • 7.9.1. Brazil
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Competitive scenario
    • 7.9.1.3. Regulatory framework
    • 7.9.1.4. Reimbursement scenario
    • 7.9.1.5. Brazil market estimates and forecasts, 2018 - 2030
  • 7.9.2. Argentina
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Competitive scenario
    • 7.9.2.3. Regulatory framework
    • 7.9.2.4. Reimbursement scenario
    • 7.9.2.5. Argentina market estimates and forecasts, 2018 - 2030
• 7.10. MEA
  • 7.10.1. South Africa
    • 7.10.1.1. Key country dynamics
    • 7.10.1.2. Competitive scenario
    • 7.10.1.3. Regulatory framework
    • 7.10.1.4. Reimbursement scenario
    • 7.10.1.5. South Africa market estimates and forecasts, 2018 - 2030
  • 7.10.2. Saudi Arabia
    • 7.10.2.1. Key country dynamics
    • 7.10.2.2. Competitive scenario
    • 7.10.2.3. Regulatory framework
    • 7.10.2.4. Reimbursement scenario
    • 7.10.2.5. Saudi Arabia market estimates and forecasts, 2018 - 2030
  • 7.10.3. UAE
    • 7.10.3.1. Key country dynamics
    • 7.10.3.2. Competitive scenario
    • 7.10.3.3. Regulatory framework
    • 7.10.3.4. Reimbursement scenario
    • 7.10.3.5. UAE market estimates and forecasts, 2018 - 2030
  • 7.10.4. Kuwait
    • 7.10.4.1. Key country dynamics
    • 7.10.4.2. Competitive scenario
    • 7.10.4.3. Regulatory framework
    • 7.10.4.4. Reimbursement scenario
    • 7.10.4.5. Kuwait market estimates and forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
  • 8.2.1. Innovators
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. AxoGen, Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Stryker
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Baxter International, Inc.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Polyganics BV
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Integra LifeSciences
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Renerva, LLC.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Newrotex
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Toyobo Co., Ltd.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Orthocell Ltd
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives

관련자료